A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
for Colorectal Cancer
22 locations incl. Huntsville
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT07023289·Phase 2·Recruiting